Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640748 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19656665 | 0.89 | ALDH1A1 (0.38) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640756 | 0.83 | CNR1 (0.45) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640389 | 0.81 | ALDH1A1 (0.33) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640390 | 0.81 | ALDH1A1 (0.33) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640632 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL19640631 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL19640752 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640751 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTCNR1FAAHCNR2 | |
| SCHEMBL19640553 | 0.78 | EPHX2 (0.48) | ALDH1A1MAPTCNR1FAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | ALDH1A1 1220/4885MAPT 867/4885CNR1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.